Allos Therapeutics to Report First Quarter 2009 Results on May 5, 2009
28 Avril 2009 - 10:00PM
Business Wire
Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical
company focused on developing and commercializing innovative small
molecule drugs for the treatment of cancer, today announced that
Company management will provide a corporate update and review of
the first quarter 2009 results via webcast and conference call on
Tuesday, May 5, 2009 at 4:30 p.m. ET.
The webcast of this call will be available from the homepage and
the investors/media section of the Company's Web site,
www.allos.com. Alternatively, callers may participate in the
conference call by dialing 877-941-1465 (domestic) or
480-629-9677(international). Participants should reference the
Allos Therapeutics conference call. Webcast and telephone replays
of the conference call will be available approximately two hours
after the completion of the call through Friday, May 15, 2009. To
access the replay, callers should dial 1-800-406-7325 (domestic) or
303-590-3030 (international) and use passcode 4060691#.
About Allos Therapeutics, Inc.
Allos Therapeutics is a biopharmaceutical company focused on
developing and commercializing innovative small molecule drugs for
the treatment of cancer. The Company�s lead product candidate,
pralatrexate, is a targeted antifolate designed to accumulate
preferentially in cancer cells. In February 2009, the Company
announced the final results from PROPEL, the Company�s pivotal
Phase 2 trial of pralatrexate in patients with relapsed or
refractory peripheral T-cell lymphoma (PTCL). The PROPEL trial was
conducted under an agreement reached with the U.S. Food and Drug
Administration under its special protocol assessment (SPA) process.
Based on the results of the PROPEL trial, the Company submitted a
New Drug Application to the U.S. Food and Drug Administration for
pralatrexate for the treatment of relapsed or refractory PTCL in
March 2009. The Company is also investigating pralatrexate in
patients with non-small cell lung cancer, bladder cancer and a
range of lymphoma sub-types. The Company currently retains
exclusive worldwide rights to pralatrexate for all indications. For
additional information, please visit www.allos.com.
Safe Harbor Statement
The 2009 first quarter results press release and conference call
will contain forward-looking statements that involve significant
risks and uncertainties, including those contained in the "Risk
Factors" section of the Company's Form 10-K for the year ended
December 31, 2008 and in the Company's other periodic reports and
filings with the Securities and Exchange Commission. Allos is
providing the information contained in the press release and
conference call as of the date of the release and does not
undertake any obligation to update any forward-looking statements
as a result of new information, future events or otherwise. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in the press release or the
conference call. No forward-looking statement can be guaranteed and
actual events and results may differ materially from those
projected.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Allos Therapeutics, Inc.